DEANNE GARAY: Open Payments
NPI 1417356387 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$786 in 40 payments from 9 companies in 2025. Trend: 2023 $1,371 · 2024 $440 · 2025 $786
Food & beverage: $786
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $217 |
| Janssen Pharmaceuticals, Inc | 6 | $148 |
| Supernus Pharmaceuticals, Inc. | 4 | $82 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $79 |
| Vanda Pharmaceuticals Inc. | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Alkermes, Inc. | 1 | $25 |
Products named: VRAYLAR, Qelbree, INVEGA SUSTENNA, CAPLYTA, FANAPT, SPRAVATO, TRINTELLIX, Auvelity.
Industry payments across TX — which companies pay providers there.
